biogenerics News

Recently published report Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 will provide you with information that you need to understand current trends and future possibilities for those drugs.

A multidisciplinary team of researches specialized on Biotechnology, Biomedicine, Science and Environmental sciences, will research in new processes for the biosimilars production.

Un equipo multidisciplinar de la Universidad, de Biotecnología, Ciencias y Medio Ambiente, investigará en productos biogenéricos

The biosimilars production has been incorporate to the new technological platforms of Curaxys in order to get more competitive processes and products. Curaxys has been pioneer in the use of those technologies, mainly in the baculovirus expression sys

Curaxys is the new company specialized in the production of biosimilars medicines. It is an independent private company, located on the technological park of Cadiz (Spain). The new venture is focuses in the development of new technological platform f

There is great demand for lower-cost biological drugs: commercial and regulatory developments will make biosimilars and follow-on biologics a success – our new report explains how- Revenues for biologic drugs reached approximately $125bn in 2008.